Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 14, 2009
Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignanciesMehdi Hamadani, William Blum, Gary Phillips, et al.
Leukemia Research|July 23, 2013
Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemiaDeborah M Stephens, Amy S Ruppert, Kami Maddocks, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 26, 2021
A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaVincent Ribrag, Seung Tae Lee, David Rizzieri, et al.
Oncotarget|April 24, 2016
Hsp90 inhibition increases SOCS3 transcript and regulates migration and cell death in chronic lymphocytic leukemiaTimothy L Chen, Nikhil Gupta, Amy Lehman, et al.
Blood|June 5, 2010
Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signalsSarah E M Herman, Amber L Gordon, Amy J Wagner, et al.
Bone Marrow Transplantation|February 16, 2018
Psychosocial risk predicts high readmission rates for hematopoietic cell transplant recipientsDaniel R Richardson, Ying Huang, Heather L McGinty, et al.
British Journal of Haematology|May 12, 2010
Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylationKristie A Blum, Zhongfa Liu, David M Lucas, et al.
Hematological Oncology|March 2, 2011
Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioningMehdi Hamadani, Michael Craig, Gary S Phillips, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 9, 2016
Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host DiseaseSumithira Vasu, Susan Geyer, Anissa Bingman, et al.
Blood|July 9, 2014
PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLLDalia El-Gamal, Katie Williams, Taylor D LaFollette, et al.
Pageof 4